Nippon Chemiphar Co., Ltd. (TYO:4539)
1,768.00
+18.00 (1.03%)
Feb 13, 2026, 3:30 PM JST
Nippon Chemiphar Revenue
Nippon Chemiphar had revenue of 8.33B JPY in the quarter ending December 31, 2025, a decrease of -4.10%. This brings the company's revenue in the last twelve months to 32.52B, up 1.67% year-over-year. In the fiscal year ending March 31, 2025, Nippon Chemiphar had annual revenue of 32.57B with 5.93% growth.
Revenue (ttm)
32.52B
Revenue Growth
+1.67%
P/S Ratio
0.20
Revenue / Employee
38.04M
Employees
855
Market Cap
6.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 32.57B | 1.82B | 5.93% |
| Mar 31, 2024 | 30.75B | -811.00M | -2.57% |
| Mar 31, 2023 | 31.56B | -947.00M | -2.91% |
| Mar 31, 2022 | 32.51B | 965.00M | 3.06% |
| Mar 31, 2021 | 31.54B | -215.00M | -0.68% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 66.38B |
| Fuso Pharmaceutical Industries,Ltd. | 62.05B |
| Morishita Jintan | 12.90B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 5.94B |
| WDB coco | 4.98B |
| SymBio Pharmaceuticals | 1.31B |
| Solasia Pharma K.K. | 326.00M |